Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Optinose Inc (NQ: OPTN ) 0.6900 -0.0135 (-1.92%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Optinose Inc < Previous 1 2 Next > Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 16, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Appoints Terry Kohler as Chief Financial Officer October 07, 2024 From Optinose, Inc. Via GlobeNewswire New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery September 05, 2024 From Optinose, Inc. Via GlobeNewswire Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference August 26, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights August 08, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Announces Reporting Date for Second Quarter 2024 Financial Results August 02, 2024 Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time From Optinose, Inc. Via GlobeNewswire Expanded Access to XHANCE with Addition to National Commercial Formularies June 27, 2024 From Optinose, Inc. Via GlobeNewswire Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 17, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights May 14, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Announces Reporting Date for First Quarter 2024 Financial Results May 10, 2024 Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time From Optinose, Inc. Via GlobeNewswire Optinose Announces $55 Million Registered Direct Offering May 09, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million April 25, 2024 Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time From Optinose, Inc. Via GlobeNewswire Optinose to Present at the Needham Virtual Healthcare Conference April 04, 2024 From Optinose, Inc. Via GlobeNewswire XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps March 15, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights March 07, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results February 29, 2024 Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time From Optinose, Inc. Via GlobeNewswire Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice January 18, 2024 From Optinose, Inc. Via GlobeNewswire Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE December 06, 2023 From Optinose, Inc. Via GlobeNewswire Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference November 22, 2023 From Optinose, Inc. Via GlobeNewswire Optinose Reports Third Quarter 2023 Financial Results and Operational Updates November 09, 2023 From Optinose, Inc. Via GlobeNewswire Optinose Announces Reporting Date for Third Quarter 2023 Financial Results October 27, 2023 Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time From Optinose, Inc. Via GlobeNewswire Optinose to Present at the 2023 Cantor Global Healthcare Conference September 22, 2023 From Optinose, Inc. Via GlobeNewswire Optinose Reports Second Quarter 2023 Financial Results and Operational Updates August 10, 2023 From Optinose, Inc. Via GlobeNewswire Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million July 27, 2023 From Optinose, Inc. Via GlobeNewswire Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 16, 2023 From Optinose, Inc. Via GlobeNewswire Optinose to Present at the Jefferies Healthcare Conference June 02, 2023 From Optinose, Inc. Via GlobeNewswire Optinose Reports First Quarter 2023 Financial Results and Operational Updates May 11, 2023 From Optinose, Inc. Via GlobeNewswire Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE May 04, 2023 From Optinose, Inc. Via GlobeNewswire Optinose Announces Reporting Date for First Quarter 2023 Financial Results May 01, 2023 Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time From Optinose, Inc. Via GlobeNewswire Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 18, 2023 From Optinose, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
